The purpose of the study is to learn how well the medicine works and how safe it is in adult men who have not received prior treatment for the condition. Participants will take the study drug every day for about a year and a half, with regular clinic visits where blood samples, urine samples, and simple kidney checks are performed to follow any changes.

The main goal is to see whether the amount of the fatty substance in the tiny blood vessels of the kidney decreases over time, and a secondary goal is to see if the level of the substance in the blood changes. Throughout the trial, doctors will monitor participants for any side effects and will collect information to assess both effectiveness and safety.

The main aim of the study is to compare how each approach affects body weight after six months.

Participants will be assigned by chance to one of the treatment groups and will follow the assigned plan for up to one year. Throughout the study, regular visits will be scheduled to record weight, check blood pressure, cholesterol levels, and blood sugar, and to monitor any side effects. The study does not involve any invasive procedures, and all information is collected in a routine clinical setting.

The purpose of the study is to compare how well the two treatments lower LDL‑C after eight weeks. Participants are randomly assigned to receive the combination tablet, the standard medication, or a placebo, and they take the assigned pill once daily for about two months. During this time they attend a few clinic visits where blood samples are taken to check cholesterol levels.

In addition to LDL‑C, the study also measures changes in Apo B, non‑HDL‑C, and total cholesterol, which are other indicators of heart risk. Blood tests are done at the start and at the end of the eight‑week period to see how each measure changes. The study follows participants only for the short treatment period and does not involve any other procedures.

The purpose of the study is to determine if Eloralintide is more effective than a placebo at helping to change body weight. During the study, participants will be assigned to receive either the active medication or a placebo once every week. The process is double-blind, meaning that neither the participants nor the researchers know who is receiving the actual drug or the inactive substance until the study is complete. Participants will be monitored over a period of time to observe changes in weight and to ensure safety.

Participants will be randomly assigned to receive either the active tablet or the placebo for a period of 12 weeks. During this time, regular visits will be scheduled to check weight, waist size, and basic blood tests, and to monitor heart rhythm using an ECG. Side effects, referred to as adverse events, will be recorded, and blood samples will be taken to study the drug’s pharmacokinetics, which describes how the medication is absorbed, distributed, and cleared from the body.

The purpose of the study is to determine whether oral semaglutide leads to greater weight loss compared with the placebo when combined with diet and exercise. Participants will take the assigned tablet every day for several months, attend regular clinic visits where their weight, waist size, blood pressure, and blood tests are checked, and report any side effects. The study will track changes in body weight and related health measures over the course of the trial.